GSK•benzinga•
GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report
Summary
ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 4, 2025 by benzinga